Browse Articles

Analysis of complement system gene expression and outcome across the subtypes of glioma

Mudda et al. | May 17, 2023

Analysis of complement system gene expression and outcome across the subtypes of glioma
Image credit: National Cancer Institute

Here the authors sought to better understand glioma, cancer that occurs in the glial cells of the brain with gene expression profile analysis. They considered the expression of complement system genes across the transcriptional and IDH-mutational subtypes of low-grade glioma and glioblastoma. Based on their results of their differential gene expression analysis, they found that outcomes vary across different glioma subtypes, with evidence suggesting that categorization of the transcriptional subtypes could help inform treatment by providing an expectation for treatment responses.

Read More...

Effects of vascular normalizing agents on immune marker expression in T cells, dendritic cells, and melanoma cells

Yaskolko et al. | Nov 03, 2021

Effects of vascular normalizing agents on immune marker expression in T cells, dendritic cells, and melanoma cells

Tertiary lymphoid structures (TLS) are lymph node-like structures that form at sites of inflammation, and their presence in cancer patients is predictive of a better clinical outcome. One significant obstacle to TLS formation is reduced immune cell infiltration into the tumor microenvironment (TME). Recent studies have shown that vasculature normalizing (VN) agents may override this defect to improve tissue perfusion and increased immune cell entry into the TME. However, their effects on immune cell and tumor cell phenotype remain understudied. Here the authors investigate whether treating tumor cells with VN would reduce their immunosuppressive phenotype and promote production of chemokine that recruit immune cells and foster TLS formation.

Read More...